{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:22:39Z","timestamp":1771395759102,"version":"3.50.1"},"reference-count":8,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xphs.2025.104071","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:05:31Z","timestamp":1763640331000},"page":"104071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Navigating PUPSIT implementation challenges for high-viscosity oligonucleotide drug products"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5969-5829","authenticated-orcid":false,"given":"Yu (Zoe)","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Perchiacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anya","family":"Batalina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6962-7130","authenticated-orcid":false,"given":"Mery","family":"George De la Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7093-3786","authenticated-orcid":false,"given":"J Anderson","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alka","family":"Prasher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4502-3751","authenticated-orcid":false,"given":"James","family":"Colandene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Munther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xphs.2025.104071_bib0001","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5731\/pdajpst.2019.011189","article-title":"Test process and results of potential masking of sterilizing-grade filters","volume":"74","author":"Ferrante","year":"2020","journal-title":"PDA J Pharm Sci Technol"},{"key":"10.1016\/j.xphs.2025.104071_bib0002","article-title":"Pre-use\/post-sterilization integrity testing (PUPSIT): to do or not to do?","author":"Gupta","year":"2019","journal-title":"PDA J Pharmaceut Sci Technol"},{"key":"10.1016\/j.xphs.2025.104071_bib0003","series-title":"EudraLex \u2013 Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products For Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products","year":"2008"},{"issue":"7","key":"10.1016\/j.xphs.2025.104071_bib0004","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.xphs.2024.04.021","article-title":"A review on commercial oligonucleotide drug products","volume":"113","author":"Vinjamuri","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104071_bib0005","series-title":"Materials Surface Processing By Directed Energy Techniques","first-page":"411","article-title":"Chapter 12 - spectroscopic analyses of surfaces and thin films","author":"Deville","year":"2006"},{"issue":"16","key":"10.1016\/j.xphs.2025.104071_bib0006","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1021\/acs.langmuir.3c03339","article-title":"Fundamentals and applications of surface wetting","volume":"40","author":"Josyula","year":"2024","journal-title":"Langmuir"},{"issue":"6","key":"10.1016\/j.xphs.2025.104071_bib0007","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1002\/jps.22045","article-title":"Adsorption behavior of a surfactant and a monoclonal antibody to sterilizing-grade filters","volume":"99","author":"Mahler","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2025.104071_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.anucene.2024.110419","article-title":"The impact of gamma-irradiation on physical properties and membrane distillation performance of PTFE and PVDF hollow fiber membrane","volume":"201","author":"Jia","year":"2024","journal-title":"Ann Nucl Energy"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925005258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:37:52Z","timestamp":1771393072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925005258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0022354925005258"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104071","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating PUPSIT implementation challenges for high-viscosity oligonucleotide drug products","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}],"article-number":"104071"}}